Company intelligence / Profile preview

ViaCyte, Inc.

San Diego, California, United States

Ownership: Private
Employees: ~200
Development stage: Other

Overview

ViaCyte developed stem cell-derived pancreatic endoderm cells that mature after transplantation and function to regulate blood glucose in rodent models. Their lead candidates included PEC-Direct and PEC-Encap for type 1 diabetes, with PEC-Direct being evaluated in Phase 1/2 trials before acquisition.

Therapeutic areas: Endocrinology
Modalities: Stem cell therapyCell replacement therapy
Industry: Biotech

Partnerships

CRISPR TherapeuticsW.L. Gore & Associates

Beyond the preview

Go deeper on ViaCyte, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViaCyte, Inc..